Breaking News Instant updates and real-time market news.

VIA

Viacom

$30.64

-0.66 (-2.11%)

, VIAB

Viacom

$25.27

-0.7 (-2.70%)

09:11
03/25/19
03/25
09:11
03/25/19
09:11

Fly Intel: Pre-market Movers

HIGHER: Viacom (VIAB), up 4.5% after media reports indicate that the company and AT&T (T) resolved their contract dispute... Avaya (AVYA), up 31% after Reuters reports the company is considering a leveraged buyout offer from a private equity firm that would value the company at more than $5B, or over $20 per share... Integrated Device (IDTI), up 2.5% after announcing with Renesas Electronics (RNECY) that they received notification by the committee on Foreign Investment in the United States that the investigation of the companies' proposed merger transaction is complete and that there are no unresolved national security concerns with respect to the transaction. UP AFTER EARNINGS: MediWound (MDWD), up 7.5%. LOWER: Phillip Morris (PM), down 1% after revising FY19 EPS view for deconsolidation of Canadian subsidiary... Proteostasis (PTI), down 56% after Phase 1 results from CFTR modulators...Recro Pharma (REPH), down 44% after announcing that it received a complete response letter from the FDA about meloxicam IV... Akamai (AKAM), down 5% after Deutsche Bank analyst Vijay Bhagavath downgraded the stock to Sell from Hold and lowered his price target for the shares to $58 from $64... Nu Skin (NUS), down 3% after Stifel analyst Mark Astrachan downgraded shares to Sell from Hold and cut his price target for the shares to $43 from $63... Tesla (TSLA), down 3% after the New York Times reported that analysts have speculated that Tesla has seen a fall in sales since the beginning of the year and said recently compiled data on new-car registrations from the U.S. appear to support that view.

VIA

Viacom

$30.64

-0.66 (-2.11%)

VIAB

Viacom

$25.27

-0.7 (-2.70%)

TSLA

Tesla

$264.58

-9.52 (-3.47%)

REPH

Recro Pharma

$5.30

-4.33 (-44.96%)

T

AT&T

$31.03

-0.05 (-0.16%)

AVYA

Avaya

$13.23

-0.74 (-5.30%)

IDTI

Integrated Device

$48.96

1.12 (2.34%)

MDWD

MediWound

$5.50

0.355 (6.90%)

PM

Philip Morris

$89.93

-0.81 (-0.89%)

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

AKAM

Akamai

$71.18

-2.22 (-3.02%)

NUS

Nu Skin

$49.35

-2.57 (-4.95%)

  • 25

    Mar

  • 25

    Mar

  • 25

    Mar

  • 24

    Apr

  • 26

    Apr

  • 07

    May

  • 20

    May

  • 06

    Jun

VIA Viacom
$30.64

-0.66 (-2.11%)

03/13/19
03/13/19
DOWNGRADE
Target $66

Neutral
Roku downgraded to Neutral after 160% rally off lows at Macquarie
As previously reported, Macquarie analyst Tim Nollen downgraded Roku to Neutral from Outperform following a 162% rise in the stock from its lows since Christmas. He sees the stock's current valuation as full given the rising competition in the ad-supported video on-demand, or AVOD, area from services such as Viacom's (VIAB) Pluto TV, Amazon's (AMZN) ad-supported channels and a potential service expected to be announced by Apple (AAPL) on March 25. Nollen raised his price target on Roku shares to $66 from $57.
02/05/19
IMPC
02/05/19
NO CHANGE
IMPC
Imperial Capital raises FY19 estimates on Viacom after Q1 beat
Imperial Capital analyst Megan Barnett maintained an Outperform rating and $37 price target on Viacom shares, after Viacom beat the firm's and consensus estimates when it reported Q1 results. Barnett raised her FY19 EPS estimate for Viacom to $1.12 from $1.02 due to the company's Q1results.
01/24/19
SOCG
01/24/19
DOWNGRADE
SOCG
Hold
Viacom downgraded to Hold from Buy at Societe Generale
01/15/19
01/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIA, VIAB) upgraded to Buy from Hold at Pivotal Research with analyst Brian Wieser citing valuation. 2. Citi (C) upgraded to Outperform from Market Perform at BMO Capital with analyst James Fotheringham saying the bank's Q4 earnings and outlook were "just fine," but the stock trades "as if tragedy were nigh" at a 2-year forward multiple of 6.3-times earnings relative to the average historical valuation of 9.5-times. 3. Grainger (GWW) upgraded to Outperform from Neutral at Macquarie. 4. Helmerich & Payne (HP) upgraded to Overweight from Neutral at JPMorgan with analyst Sean Meakim saying while Helmerich is not immune from lower exploration and production spending, there is too much pessimism on the company's ability to sustain EBITDA in such an environment. 5. Akamai (AKAM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss citing his increased confidence in durable high single digit revenue growth and margins improving. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VIAB Viacom
$25.27

-0.7 (-2.70%)

02/06/19
BRRR
02/06/19
NO CHANGE
Target $35
BRRR
Outperform
Barrington expects Pluto TV to accelerate momentum in key Viacom demographics
Barrington analyst James Goss kept his Outperform rating and $35 price target on Viacom with a positive view of its Pluto TV platform as a component of its direct-to-consumer strategy. The analyst sees the services as an "important link for Viacom in accessing its young target demo" in a form factor "attractive to the user base". While not expected to make a meaningful impact on Q2, Goss adds that Pluto TV offers the "ability to distribute and monetize the cable network group's significant IP portfolio".
TSLA Tesla
$264.58

-9.52 (-3.47%)

03/25/19
BARD
03/25/19
NO CHANGE
Target $65
BARD
Outperform
Carvana price target raised to $65 from $58 at Baird
Baird analyst Colin Sebastian raised his price target for Carvana (CVNA) to $65 from $58 after increasing his Q1 unit and revenue estimates above consensus. The analyst now expects Q1 retail units of 34,000, above the consensus of 32,900, on revenue of $678M, up 88% year-over-year. Tax refund flows are likely to provide a late-quarter tailwind, Sebastian tells investors in a research note. The correlation between refunds and used car sales is likely providing a boost in unit sales ahead of the Q1 quarter close, Sebastian tells investors in a research note. Further, he believes the online shift by CarMax (KMX) and Tesla (TSLA) are endorsements of the e-commerce model. The analyst remains constructive on Carvana shares citing the momentum from a seasonal uplift in car sales, positive near-term data checks, and the "massive" long-term e-commerce opportunity for used cars. He keeps an Outperform rating on Carvana.
03/25/19
LEHM
03/25/19
NO CHANGE
LEHM
Underweight
Tesla's 'conflicting' guidance has parallel universes, says Barclays
The parallel universe theory may explain Tesla's "conflicting guidance," Barclays analyst Brian Johnson tells investors in a research note titled "Parallel universes of 'guidance.'" The analyst sees "at least two, possibly three," parallel universes issuing from Tesla and its CEO Elon Musk, with a wide range of implied revenue guidance. In the first universe, the universe of regulatory filings with lawyer vetted statements, Tesla is guiding towards annual deliveries of 360,000 to 400,000 total units, Johnson writes. In the second universe, which includes Musk's oral comments, tweets and court filings, the delivery guidance is 420,000 to 600,000 vehicles, adds the analyst. The difference between the two universes is up to $10B of revenue or $8B of inventory build, Johnson contends. He keeps an Underweight rating on Tesla with a $192 price target. The stock closed Friday down $9.49 to $264.53.
03/25/19
RBCM
03/25/19
NO CHANGE
Target $210
RBCM
Underperform
Tesla price target lowered to $210 from $245 at RBC Capital
RBC Capital analyst Joseph Spak lowered his price target on Tesla to $210 and kept his Underperform rating ahead of its Q1 deliveries report expected in early April. The analyst cites "meager demand and some M3 delivery issues abroad", revising his Q1 outlook to 52.5K Tesla Model 3 deliveries from his 57K prior outlook and the consensus view of 58.4K. Spak adds that he anticipates Tesla's lower pricing to weigh on margins for the company, and he lowers his FY19 EPS view to (33c) from $4.43 and FY20 view to $1.70 from $5.71.
03/25/19
JMPS
03/25/19
NO CHANGE
Target $394
JMPS
Outperform
Tesla price target lowered to $394 from $406 at JMP Securities
JMP Securities analyst Joseph Osha reduced his 2019 and 2020 estimates for Tesla reflect continued weakness in the U.S. market as well as a partial retreat from the earlier plan to shut the dealership network down. However, he has not adjusted his unit delivery, revenue, or gross margin assumptions for 2020 and said he is still a buyer of the stock given his view that the company's current challenges do not change the underlying competitive story. Osha lowered his price target on Tesla shares to $394 from $406 but keeps an Outperform rating on the stock.
REPH Recro Pharma
$5.30

-4.33 (-44.96%)

03/25/19
ROTH
03/25/19
DOWNGRADE
ROTH
Neutral
Recro Pharma downgraded to Neutral from Buy at Roth Capital
03/25/19
OPCO
03/25/19
NO CHANGE
Target $9
OPCO
Outperform
Recro Pharma price target lowered to $9 from $19 at Oppenheimer
Oppenheimer analyst Leland Gershell lowered his price target for Recro Pharma to $9 from $19 saying that a second CRL for IV meloxicam comes as a "surprising disappointment," as he had perceived the issues that held up initial approval as relatively minor and resolvable through further negotiation between the company and the FDA. Following this recent action, the analyst now lacks clarity on approval prospects as well as on how Recro Pharma will adequately address the agency's concerns. Gershell reiterates an Outperform rating on the shares.
03/25/19
03/25/19
DOWNGRADE
Target $7.5

Neutral
Recro Pharma downgraded to Neutral after IV Meloxicam CRL at Roth Capital
As previously reported, Roth Capital analyst Scott Henry downgraded Recro Pharma to Neutral from Buy after the FDA issued a CRL to the company with regards to the pain drug IV meloxicam. The analyst notes this was not expected given the unmet need for non-opioid pain relievers, and expects Recro Pharma to pursue dispute resolution. Additionally, Henry believes that the company needs to cut costs and pursue profitability with the CDMO business near-term. The analyst also lowered his price target on the shares to $7.50 from $15.
03/25/19
PIPR
03/25/19
NO CHANGE
Target $9
PIPR
Overweight
Recro CRL disappointing, but don't ignore CDMO business, says Piper Jaffray
Piper Jaffray analyst David Amsellem lowered his price target for Recro Pharma to $9 from $12 after the company received a second Complete Response Letter from the FDA for its intravenous form of meloxicam for post-operative pain. What is clear from the CRL is that the agency has moved the goal posts on Recro, Amsellem tells investors in a research note. Two successful placebo-controlled studies along with a large safety data base, historically the standard by which agents for acute pain are evaluated, "does not pass muster in this case," says the analyst. As such, he would not be surprised to see Recro initiate a dispute resolution process. Though the latest CRL is "undoubtedly disappointing," the company's cash flows from its contract development and manufacturing organization segment are not fully appreciated at current share levels, argues Amsellem. He believes this should "provide a floor in the high-single digits per share at a minimum." The analyst reiterates an Overweight rating on Recro Pharma.
T AT&T
$31.03

-0.05 (-0.16%)

03/15/19
RAJA
03/15/19
UPGRADE
RAJA
Outperform
AT&T upgraded to Outperform from Market Perform at Raymond James
03/14/19
NEED
03/14/19
NO CHANGE
Target $85
NEED
Buy
Roku price target raised to $85 from $65 at Needham
Needham analyst Laura Martin raised her price target on Roku (ROKU) to $85 and kept her Buy rating, saying its 14% stock price decline yesterday was "overdone" while maintaining her view of the company as the "top pick for 2019". The analyst cites the company's position of an "arms dealer", aggregating 5K 3rd party streaming video apps into one platform. She also believes that "every new streaming service", including the upcoming offerings from Disney (DIS), AT&T (T) and Apple (AAPL) will sign contracts allowing for viewing on Roku device, adding that "TV advertisers" will have to follow the viewers since some 10M Roku users have no linear TV access. Moreover, Martin contends that Roku is in position to expand internationally or possibly be acquired.
03/15/19
03/15/19
UPGRADE

Outperform
AT&T upgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James upgraded AT&T to Outperform from Market Perform and established a $34 price target. Analyst Frank Louthan said AT&T shares trade at a relative discount and expects shares to be driven by positive earnings growth combined with a strong de-levering story.
03/15/19
03/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Edward Yruma saying Amazon is taking a number of operational moves to improve profitability in core retail, which could drive mid-term earnings above current consensus estimates. 2. AT&T (T) upgraded to Outperform from Market Perform at Raymond James with analyst Frank Louthan saying AT&T shares trade at a relative discount and expects shares to be driven by positive earnings growth combined with a strong de-levering story. 3. Colfax (CFX) upgraded to Equal Weight from Underweight at Barclays with analyst Julian Mitchell saying he views the company's turnaround story as underappreciated. 4. Rent-A-Center (RCII) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch citing the trial win regarding the terminated buyout with Vintage Capital and a strong fundamental outlook for the upgrade. 5. Global Net Lease (GNL) upgraded to Buy from Neutral at B. Riley FBR with analyst Bryan Maher citing the stock's attractive relative valuation as well as management's acquisition "acumen" for the upgrade to Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AVYA Avaya
$13.23

-0.74 (-5.30%)

03/11/19
GUGG
03/11/19
INITIATION
Target $22
GUGG
Buy
Avaya initiated with a Buy at Guggenheim
Guggenheim analyst Nandan Amladi started Avaya with a Buy rating and $22 price target. As a newly public company post-bankruptcy, Avaya has emerged with a "much stronger focus" on recurring revenue and an "aggressive" cloud roadmap targeting 25% of total revenue by fiscal 2021, from about 12% today, Amladi tells investors in a research note. He cites the company's combination of a "credible strategic pivot" and an "attractive valuation" for his Buy rating.
01/07/19
MSCO
01/07/19
INITIATION
Target $18.5
MSCO
Equal Weight
Avaya initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Meta Marshall initiated Avaya with an Equal Weight rating and $18.50 price target, arguing that the company has more work to do to assure they are the technology choice when their installed base looks to move towards the cloud. Avaya has the largest installed base in the industry and a growing bench of cloud products, but they have been out-executed by smaller cloud-first competitors by under utilizing a partnership ecosystem to amplify their marketing, Marshall tells investors.
01/25/19
LEHM
01/25/19
UPGRADE
Target $21
LEHM
Overweight
Avaya upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Raimo Lenschow upgraded Avaya Holdings to Overweight and raised his price target for the shares to $21 from $20.
01/25/19
LEHM
01/25/19
UPGRADE
Target $21
LEHM
Overweight
Barclays sees over 40% upside in Avaya shares, upgrades to Overweight
Barclays analyst Raimo Lenschow upgraded Avaya to Overweight from Equal Weight and raised his price target for the shares to $21 from $20. The analyst sees over 40% upside for the stock despite the company's status as a "legacy tech vendor." Since its return from bankruptcy in January 2018, Avaya has been largely ignored by equity investors and is trading at very low multiples, Lenschow tells investors in a research note. A return to legacy tech peer multiples alone could result in significant share price appreciation, says the analyst. He believes ongoing execution towards Avaya's fiscal 2019 revenue growth targets and better cash conversion will be positive catalysts.
IDTI Integrated Device
$48.96

1.12 (2.34%)

09/11/18
COWN
09/11/18
DOWNGRADE
Target $49
COWN
Market Perform
Integrated Device downgraded to Market Perform from Outperform at Cowen
Cowen analyst Karl Ackerman downgraded Integrated Device Technology to Market Perform from Outperform following the announcement of an all cash deal from Renesas. He sees a low regulatory risk of the deal closing. Ackerman raised his price target to $49 from $41 on Integrated Device shares.
10/31/18
ROTH
10/31/18
NO CHANGE
Target $24.5
ROTH
Buy
Energous Tier 1 strategic partner progressed to product engineering, says Roth Capital
Roth Capital analyst William Gibson notes that Energous's (WATT) Tier One strategic partner has progressed from technology development to actual product engineering, and a minimal number of products are likely to be commercially available this Christmas. To date, three customers have announced WattUp-enabled commercial products, including SK Telesis Delight, Gokhale Method and Qubercomm Technologies, he notes, adding that a reference design transmitter is also available from Integrated Device (IDTI). Although Gibson does not anticipate large unit sales from initial early adopters, these companies pave the way for faster regulatory approval for future products. He expects the small form factor markets to be significant revenue contributors in 2019. The analyst reiterates a Buy rating and $24.50 price target on Energous shares
10/17/18
CHLM
10/17/18
DOWNGRADE
Target $49
CHLM
Hold
Integrated Device downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Anthony Stoss downgraded Integrated Device (IDTI) to Hold from Buy, with a $49 price target. The analyst believes additional bids are unlikely to surface given the time that has passed since Renesas' (RNECY) original announcement to acquire the company.
09/11/18
PIPR
09/11/18
DOWNGRADE
PIPR
Neutral
Integrated Device downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Harsh Kumar downgraded Integrated Device (IDTI) to Neutral from Overweight citing the company's agreement to be acquired by Renesas Electronics (RNECY) for $49 per share in cash.
MDWD MediWound
$5.50

0.355 (6.90%)

03/12/19
WELS
03/12/19
NO CHANGE
Target $11
WELS
Outperform
MediWound CEO change 'occurred from a position of strength,' says Wells Fargo
After speaking to management, Wells Fargo analyst David Maris believes the CEO change at MediWound "appears to have occurred from a position of strength" after the recently announced positive Phase III data for NexoBrid and advancing strategic discussions. The analyst continues to think the company will be able to "unlock sizable value" with a strategic transaction or partnership. Further, Maris expects MediWound "will not miss a step" transitioning to new CEO Sharon Malka. He maintains an Outperform rating on the shares with an $11 price target.
09/25/18
WELS
09/25/18
NO CHANGE
Target $11
WELS
Outperform
MediWound BARDA contract 'highly value-creating,' says Wells Fargo
Wells Fargo analyst David Maris estimates MediWound's new BARDA contract to develop NexoBrid for the treatment of Sulfur Mustard injuries should be worth approximately $1 per share. The analyst views the deal as an "endorsement of the promise" of NexoBrid and the potential for longer-term government contracts if approved. He currently does not model NexoBrid government sales but believes the size of the mass casualty preparedness market could rival the burn market. Overall, the contract from the U.S. Biomedical Advanced Research and Development Authority is a "highly value-creating deal," Maris tells investors in a research note. He keeps an Outperform rating on MediWound with an $11 price target.
08/08/18
WELS
08/08/18
NO CHANGE
Target $11
WELS
Outperform
MediWound could be sold for 'substantially higher price,' says Wells Fargo
Wells Fargo analyst David Maris noted that MediWound's Chairman said on the company's earnings call that while the board previously thought it would have more clarity by its Q2 report on its previously disclosed consideration of a potential strategic transaction, the company is taking a "comprehensive and measured approach" as it is still in talks with several parties. If MediWound is able to conclude a strategic combination, it would be for "a substantially higher price" and one that contemplates cash flows beyond Maris' current assumptions, he stated. Maris keeps an Outperform rating and $11 price target on MediWound shares.
03/12/19
RHCO
03/12/19
NO CHANGE
Target $9
RHCO
Buy
MediWound may be near strategic deal, says SunTrust
After MediWound announced that CEO Gal Cohen has decided to step down, SunTrust analyst Bruce Nudell said he believes the fact that Cohen is pursuing another opportunity while retaining his share interest in MediWound, along with the lack of formal search for a successor, is "consistent with the notion that a strategic deal is near in hand." Nudell has a Buy rating and $9 price target on MediWound shares.
PM Philip Morris
$89.93

-0.81 (-0.89%)

03/25/19
SBSH
03/25/19
NO CHANGE
Target $102
SBSH
Buy
Philip Morris price target raised to $102 from $90 at Citi
Citi analyst Adam Spielman raised his price target for Philip Morris to $102 from $90 citing the general increase in stock multiples. The analyst keeps a Buy rating on the shares. He did, however, reduce his earnings estimates for 2019 by 5% and for 2020 and beyond by 6% after Philip Morris' Canadian unit went into the local equivalent of Chapter 11. So far Canadian litigation has had little visible impact on tobacco shares, even for British American Tobacco (BTI), where the damages are much greater, Spielman tells investors in a research note. He thinks earnings reductions will affect Philip Morris in the short-term. However, in the medium-term the company's value will be determined by its success with reduced risk products, most notably iQos, says the analyst.
03/06/19
MSCO
03/06/19
NO CHANGE
MSCO
Resignation of Gottlieb lowers near-term overhang on Altria, says Morgan Stanley
Morgan Stanley analyst Pamela Kaufman said she expects a positive reaction in tobacco stocks to the news that FDA Commissioner Scott Gottlieb will resign in April as it likely delays the agency's near-term tobacco control objectives. Gottlieb has been very vocal on tobacco regulation and his resignation creates a vacuum in leadership and uncertainty about the agency's strategy for tobacco control until a new head is appointed, though leadership at the Center of Tobacco Products remains intact under Mitch Zeller, Kaufman tells investors. While his resignation reduces the near-term regulatory overhang on Altria (MO), it could be a "mixed bag for e-cigs," as Gottlieb changed his tone last year due to the youth e-cig epidemic but he had previously increased leniency towards the category when he pushed out the PMTA deadline to 2022 from 2018, added Kaufman.
03/06/19
JEFF
03/06/19
NO CHANGE
JEFF
Gottlieb resignation positive for tobacco sentiment, says Jefferies
The resignation of FDA commissioner Scott Gottlieb is a net positive for tobacco sentiment, particularly for British American Tobacco (BTI) as it should lessen concerns related to any possible action around a menthol ban near term, Jefferies analyst Owen Bennett tells investors in a research note. A potential delay to guidelines around e-vapour restrictions could also support both British American and Imperial Brands (IMBBY), adds the analyst.
02/27/19
02/27/19
UPGRADE

Fly Intel: Top analyst upgrades
Catch up on today's top analyst upgrades with this list compiled by The Fly: 1. Philip Morris (PM) upgraded to Buy from Neutral at UBS with analyst Robert Rampton saying the company's valuation hinges on its heated tobacco proposition, iQOS. 2. Boise Cascade (BCC) upgraded to Buy from Neutral at DA Davidson with analyst Steven Chercover saying that with the "irrational exuberance" having been shaken out of the stock, now is an "attractive entry point." 3. AptarGroup (ATR) upgraded to Outperform from Neutral at Baird. 4. W. R. Berkley (WRB) upgraded to Outperform from Neutral at Credit Suisse, while Cincinnati Financial (CINF) was upgraded to Neutral from Underperform. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PTI Proteostasis
$4.17

-0.14 (-3.25%)

12/17/18
PIPR
12/17/18
NO CHANGE
PIPR
Proteostasis deal with Genentech strenghtens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $14 price target on Proteostasis (PTI), noting the company announced an agreement with Roche's (RHHBY) Genentech to license small molecule modulators of an undisclosed target that lie outside of Cystic Fibrosis, which makes the company eligible for $100M in upfront and milestone payments plus royalties. Tenthoff sees this deal strengthening Proteostasis' balance sheet. Additionally, Tenthoff is optimistic on Proteostasis' TripleRx combo, and expects full Phase I TripleRx data in Q1 of 2019. Longer term, the analyst anticipates TripleRx approval in 2021, with global sales of $2.0B by 2026.
11/07/18
11/07/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Linde plc (LIN) initiated with a Market Perform at BMO Capital. 2. Posco (PKX) initiated with an Equal Weight at Morgan Stanley. 3. Proteostasis (PTI) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/18
PIPR
11/07/18
NO CHANGE
Target $14
PIPR
Overweight
Piper Jaffray sees 'huge valuation disconnect' between Proteostasis, Vertex
Piper Jaffray analyst Edward Tenthoff notes that Proteostasis (PTI) ended Q3 with cash of $46M million subsequently completed an equity financing and sold 1.4M shares through an ATM, bringing pro forma cash to about $138M, which he estimates will fund the company into 2020. The primary driver remains initial Phase I data on Proteostasis' proprietary TripleRx regimen in homozygous F508del Cystic Fibrosis this quarter, he contends, adding that he remains encouraged based on recently reported positive Phase I data on proprietary CFTR potentiator PTI-808 and corrector PTI-801 in homozygous F508del CF patients. The analyst sees a "huge valuation disconnect" between Proteostasis and CF market leader Vertex (VRTX), and reiterates an Overweight rating and $14 price target on the former's shares.
11/07/18
CANT
11/07/18
INITIATION
Target $21
CANT
Overweight
Cantor sees 'clear opportunity' for Proteostasis, starts at Overweight
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Proteostasis (PTI) with an Overweight rating and $21 price target. Proteostasis is developing CFTR modulator therapies for the treatment of cystic fibrosis, Piros tells investors in a research note. The analyst sees a "clear opportunity" for Proteostasis to carve out a good portion of the market and make a name for itself in CF. Vertex (VRTX) has opened the door for developing CFTR modulators, says Piros.
AKAM Akamai
$71.18

-2.22 (-3.02%)

03/25/19
DBAB
03/25/19
DOWNGRADE
Target $58
DBAB
Sell
Akamai downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath downgraded Akamai Technologies to Sell from Hold and lowered his price target for the shares to $58 from $64.
03/21/19
EVER
03/21/19
INITIATION
Target $70
EVER
In Line
Akamai initiated with an In Line, valuation fair, says Evercore ISI
As previously reported, Evercore ISI initiated Akamai with an In Line and $70 price target. Analyst Ken Talanian believes new business for the year could slow and views shares as fairly valued.
03/21/19
EVER
03/21/19
INITIATION
Target $70
EVER
In Line
Akamai initiated with an In Line at Evercore ISI
Evercore analyst Ken Talanian initiated Akamai with an In Line and $70 price target.
03/25/19
DBAB
03/25/19
DOWNGRADE
Target $58
DBAB
Sell
Deutsche Bank downgrades Akamai to Sell, sees 20% share downside
Deutsche Bank analyst Vijay Bhagavath downgraded Akamai Technologies to Sell from Hold and lowered his price target for the shares to $58 from $64. The analyst's estimates for fiscal 2019 through fiscal 2021 are below consensus for both sales and earnings. He's calling for 20% downside to current share levels. While Bhagavath sees little risk to March quarter expectations, he sees an "in line to light" sales outlook for the June quarter for Akamai. His downgrade to Sell is based on fundamentals.
NUS Nu Skin
$49.35

-2.57 (-4.95%)

12/12/18
DADA
12/12/18
NO CHANGE
Target $88
DADA
Buy
Nu Skin price target lowered to $88 from $92 at DA Davidson
DA Davidson analyst Linda Bolton Weiser lowered her price target on Nu Skin to $88 after meeting with its CFO Mark Lawrence in a Holiday Beauty Bus Tour. The analyst states that while he was upbeat about the company's 3-pillar growth strategy around "Platforms, Products, and Programs", her lower price target is driven by the assumption of lower 2019 gross margins as the company's "lower margin manufacturing operations are likely to grow faster than the overall business". Weiser also lowers her FY19 EPS view by 15c to $4.00 but maintains a Buy rating on Nu Skin shares longer term on expectations that the company will gradually phase out its "limited time offers", thereby reducing the lumpiness of its sales growth rate.
10/10/18
10/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Take-Two (TTWO) initiated with an Outperform at Bernstein. 2. Shake Shack (SHAK) initiated with a Hold at Stifel. 3. Nu Skin (NUS) initiated with a Buy at DA Davidson. 4. Micron (MU) initiated with a Neutral at Piper Jaffray. 5. Crispr Therapeutics (CRSP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
STFL
03/25/19
DOWNGRADE
Target $43
STFL
Sell
Nu Skin downgraded to Sell from Hold at Stifel
Stifel analyst Mark Astrachan downgraded Nu Skin Enterprises to Sell from Hold and cut his price target for the shares to $43 from $63. The analyst sees increasing uncertainty surrounding direct selling companies in China relating to the investigation announced in January into the unlawful promotion and sale of health products. Further, the recent death of a Nu Skin registered customer who refused medical treatment believing company products would treat illness resulted in the company being cited in two communist party publications, Beijing Youth Daily and China Daily, with the latter calling for an investigation into the woman's death and Nu Skin's misleading advertising, Astrachan tells investors in a research note. The analyst admits he's unable to determine whether an investigation will be undertaken, but he says the mention in prominent party publications is reminiscent of events in 2014 that ultimately resulted in Nu Skin suspending meetings and recruitment, resulting in sales declines for two years in China. Astrachan cites increasing regulatory concerns in China for his downgrade of Nu Skin shares to Sell.
11/21/18
TIGR
11/21/18
NO CHANGE
TIGR
Strong Buy
Nu Skin pullback a buying opportunity, says Tigress Financial
Tigress Financial analyst Ivan Feinseth said he views the recent pullback in shares of Nu Skin as a buying opportunity, citing his belief that the company will continue to benefit from the growing global trend of entrepreneurialism and the global aging population. He reiterates his Strong Buy rating on Nu Skin shares.

TODAY'S FREE FLY STORIES

MRPLY

Mr Price Group

$0.00

(0.00%)

20:14
12/15/19
12/15
20:14
12/15/19
20:14
Upgrade
Mr Price Group rating change  »

Mr Price Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$341.67

-4.795 (-1.38%)

18:48
12/15/19
12/15
18:48
12/15/19
18:48
Periodicals
Boeing considering halting or cutting 737 MAX production, WSJ reports »

Boeing (BA) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEL

Xcel Energy

$62.27

0.91 (1.48%)

18:42
12/15/19
12/15
18:42
12/15/19
18:42
Initiation
Xcel Energy initiated at Goldman Sachs »

Xcel Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQUA

Evoqua Water

$19.53

-0.6 (-2.98%)

18:38
12/15/19
12/15
18:38
12/15/19
18:38
Recommendations
Evoqua Water analyst commentary at Stifel »

Evoqua Water price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:33
12/15/19
12/15
18:33
12/15/19
18:33
Upgrade
Bluescope Steel rating change at JPMorgan »

Bluescope Steel upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

16:54
12/15/19
12/15
16:54
12/15/19
16:54
Upgrade
Bluescope Steel rating change at Macquarie »

Bluescope Steel upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$72.82

0.23 (0.32%)

16:36
12/15/19
12/15
16:36
12/15/19
16:36
Recommendations
Stifel adds Sage to Select List, says SAGE-217 will generate billions »

Stifel analyst Paul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$64.79

-1.39 (-2.10%)

16:10
12/15/19
12/15
16:10
12/15/19
16:10
Earnings
DuPont sees 2019 operating EBITDA at low end of guidance range »

DuPont reconfirms its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:07
12/15/19
12/15
16:07
12/15/19
16:07
Earnings
IFF affirms existing 2019 guidance for sales and earnings »

IFF is affirming its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:05
12/15/19
12/15
16:05
12/15/19
16:05
Hot Stocks
IFF, DuPont unit see revenue growth in mid-single digits over long term »

The company created by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$103.99

1.085 (1.05%)

, MAT

Mattel

$13.35

0.58 (4.54%)

16:03
12/15/19
12/15
16:03
12/15/19
16:03
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

HAS

Hasbro

$103.99

1.085 (1.05%)

MAT

Mattel

$13.35

0.58 (4.54%)

FNKO

Funko

$15.16

0.23 (1.54%)

JAKK

JAKKS Pacific

$0.94

-0.0244 (-2.54%)

BBW

Build-A-Bear

$2.70

-0.05 (-1.82%)

MAS

Masco

$47.00

-0.44 (-0.93%)

FBHS

Fortune Brands

$65.09

-0.42 (-0.64%)

SPY

SPDR S&P 500 ETF Trust

$317.27

0.13 (0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:03
12/15/19
12/15
16:03
12/15/19
16:03
Hot Stocks
IFF to merge with DuPont's Nutrition & Biosciences unit via Reverse Morris Trust »

IFF (IFF) and DuPont (DD)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:58
12/15/19
12/15
15:58
12/15/19
15:58
Hot Stocks
Breaking Hot Stocks news story on International Flavors, DuPont »

DuPont to receive…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:58
12/15/19
12/15
15:58
12/15/19
15:58
Hot Stocks
Breaking Hot Stocks news story on International Flavors, DuPont »

DuPont holders will own…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:57
12/15/19
12/15
15:57
12/15/19
15:57
Recommendations
International Flavors, DuPont analyst commentary  »

International Flavors to…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILL

Bill.com

$38.59

3.09 (8.70%)

, EH

Ehang

$12.87

0.39 (3.13%)

15:25
12/15/19
12/15
15:25
12/15/19
15:25
On The Fly
Opening Day: XP finishes first week higher, Sprout Social lower »

This past week saw six…

BILL

Bill.com

$38.59

3.09 (8.70%)

EH

Ehang

$12.87

0.39 (3.13%)

HCCO

Healthcare Merger Corp.

$0.00

(0.00%)

OCFT

OneConnect

$10.08

(0.00%)

SPT

Sprout Social

$16.76

(0.00%)

XP

XP

$37.61

3.235 (9.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNE

Sony

$67.60

0.285 (0.42%)

, SCOR

comScore

$4.63

-0.41 (-8.13%)

15:09
12/15/19
12/15
15:09
12/15/19
15:09
Hot Stocks
Sony's 'Jumanji' tops weekend box office with $60.1M in sales »

Sony's (SNE)…

SNE

Sony

$67.60

0.285 (0.42%)

SCOR

comScore

$4.63

-0.41 (-8.13%)

DIS

Disney

$146.37

0.4 (0.27%)

LGF.A

Lionsgate

$9.68

-0.315 (-3.15%)

LGF.B

Lionsgate

$9.00

-0.35 (-3.74%)

T

AT&T

$38.24

-0.11 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

DLTR

Dollar Tree

$93.59

1.04 (1.12%)

, DG

Dollar General

$154.75

-0.885 (-0.57%)

14:31
12/15/19
12/15
14:31
12/15/19
14:31
Periodicals
Local governments want dollar stores selling fresh food, WSJ reports »

Local governments across…

DLTR

Dollar Tree

$93.59

1.04 (1.12%)

DG

Dollar General

$154.75

-0.885 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELUXY

Electrolux

$0.00

(0.00%)

14:25
12/15/19
12/15
14:25
12/15/19
14:25
Hot Stocks
Electrolux sees $70M charge in Q4 from North America consolidation »

Electrolux provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$9.74

0.655 (7.21%)

, BP

BP

$36.95

-0.005 (-0.01%)

10:39
12/15/19
12/15
10:39
12/15/19
10:39
Recommendations
Barclays, BP, Amadeus IT Group, Anglo American, BT Group, Carlsberg, Demant, E.ON, Intertek, Novartis, Persimmon, Puma, RSA Insurance, Koninklijke Vopak, Hammerson, NMC Health, Reckitt Benckiser, Renault analyst commentary  »

Jefferies gives European…

BCS

Barclays

$9.74

0.655 (7.21%)

BP

BP

$36.95

-0.005 (-0.01%)

AMADY

Amadeus IT Group

$0.00

(0.00%)

NGLOY

Anglo American

$0.00

(0.00%)

BT

BT Group

$0.00

(0.00%)

CABGY

Carlsberg

$0.00

(0.00%)

WILYY

Demant

$0.00

(0.00%)

EONGY

E.ON

$0.00

(0.00%)

IKTSY

Intertek

$0.00

(0.00%)

NVS

Novartis

$93.00

-0.055 (-0.06%)

PSMMY

Persimmon

$0.00

(0.00%)

PUMSY

Puma

$0.00

(0.00%)

RSNAY

RSA Insurance

$0.00

(0.00%)

VOPKY

Koninklijke Vopak

$0.00

(0.00%)

HMSNF

Hammerson

$0.00

(0.00%)

NMHLY

NMC Health

$0.00

(0.00%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 23

    Mar

SNE

Sony

$67.60

0.285 (0.42%)

, SCOR

comScore

$4.63

-0.41 (-8.13%)

05:55
12/15/19
12/15
05:55
12/15/19
05:55
Hot Stocks
Sony's 'Jumanji' tops weekend box office with $60.1M in sales »

Sony's (SNE)…

SNE

Sony

$67.60

0.285 (0.42%)

SCOR

comScore

$4.63

-0.41 (-8.13%)

DIS

Disney

$146.37

0.4 (0.27%)

LGF.A

Lionsgate

$9.68

-0.315 (-3.15%)

LGF.B

Lionsgate

$9.00

-0.35 (-3.74%)

T

AT&T

$38.24

-0.11 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

, AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

04:55
12/15/19
12/15
04:55
12/15/19
04:55
Conference/Events
Roth Capital to hold a conference »

8th Annual ROTH Deer…

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

BBSI

Barrett Business

$93.18

1.82 (1.99%)

BNGO

Bionano Genomics

$1.02

0.01 (0.99%)

IRMD

iRadimed

$25.25

-0.52 (-2.02%)

FC

Franklin Covey

$35.21

-0.57 (-1.59%)

NBEV

New Age Beverages

$1.91

-0.015 (-0.78%)

WATT

Energous

$1.99

(0.00%)

EAST

Eastside Distilling

$2.79

-0.12 (-4.12%)

DCTH

Delcath Systems

$0.00

(0.00%)

BOOM

DMC Global

$52.89

0.64 (1.22%)

CLAR

Clarus

$13.47

-0.02 (-0.15%)

JRSH

Jerash Holdings

$6.46

(0.00%)

MCHX

Marchex

$3.68

0.03 (0.82%)

JYNT

Joint Corp.

$17.37

0.28 (1.64%)

SOLY

Soliton

$10.35

-0.005 (-0.05%)

SMSI

Smith Micro

$4.66

0.095 (2.08%)

PWFL

PowerFleet

$6.10

0.05 (0.83%)

OSIS

OSI Systems

$100.60

0.63 (0.63%)

LOVE

Lovesac

$10.80

-1.01 (-8.55%)

VERI

Veritone

$2.73

-0.1 (-3.53%)

WTER

Alkaline Water

$1.09

-0.01 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 29

    Jan

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

, PYPL

PayPal

$107.68

2.01 (1.90%)

13:57
12/14/19
12/14
13:57
12/14/19
13:57
Periodicals
PNC clients having trouble connecting to PayPal's Venmo, WSJ reports »

Many of PNC…

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

PYPL

PayPal

$107.68

2.01 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 15

    Jan

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

, CMCSA

Comcast

$43.59

0.57 (1.33%)

07:44
12/14/19
12/14
07:44
12/14/19
07:44
Periodicals
Berkshire, Anthem among Barron's top 10 stock picks for 2020 »

Barron's has…

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

RDS.B

Royal Dutch Shell

$57.41

-0.19 (-0.33%)

RDS.A

Royal Dutch Shell

$57.44

-0.32 (-0.55%)

PFE

Pfizer

$38.31

-0.23 (-0.60%)

VIAC

ViacomCBS

$38.62

0.83 (2.20%)

ANTM

Anthem

$284.14

-0.405 (-0.14%)

DELL

Dell Technologies

$49.39

-0.11 (-0.22%)

GOOG

Alphabet

$1,348.07

-2.09 (-0.15%)

GOOGL

Alphabet Class A

$1,347.11

-1.4 (-0.10%)

UHAL

Amerco

$360.28

7.57 (2.15%)

UTX

United Technologies

$148.99

-0.5 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Feb

PCG

PG&E

$11.26

-0.49 (-4.17%)

07:38
12/14/19
12/14
07:38
12/14/19
07:38
Hot Stocks
California Governor says PG&E restructuring plan 'falls woefully short' »

California Governor Gavin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.